Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-masked, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Oral BI 1815368 in Participants With Centre-involved Diabetic Macular Edema for 48 Weeks of Treatment (THULITE)

NCT06962839 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06962839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06962839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-masked, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Oral BI 1815368 in Participants With Centre-involved Diabetic Macular Edema for 48 Weeks of Treatment (THULITE)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Recruiting
Start date
June 5, 2025
Completion date
September 29, 2027
Enrollment
300 (estimated)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

macular edema